4 Covid-19 vaccines may soon enter the clinical-trial stage: Harsh Vardhan

There are over 100 candidate vaccines which are at different levels of development

pharma
He said the Department of Biotechnology of the Ministry of Science and Technology is helping the academic world and industry in all manners
Press Trust of India New Delhi
2 min read Last Updated : May 25 2020 | 6:30 AM IST
Union Health Minister Harsh Vardhan on Sunday said that at least four of the 14 candidate vaccines for novel coronavirus in the country may enter the clinical trial stage very soon.

In a social media interaction with BJP leader G V L Narasimha Rao, the Minister said within five months, four of the vaccine candidates in the country may enter the clinical trial stage.


Rao asked the Health Minister about the status of the development of the vaccines in the country. The Minister said, "The whole world is trying to develop a vaccine for Covid-19.

"There are over 100 candidate vaccines which are at different levels of development. The World Health Organisation (WHO) is coordinating the efforts. India is also actively contributing in it. There are 14 candidates in India also which are at different levels..."
Vardhan said.

He said the Department of Biotechnology of the Ministry of Science and Technology is helping the academic world and industry in all manners such as giving regulatory clearances, grants or financial support, among other things. "As far as I know, four of our fourteen vaccines will soon be in the clinical trial stage, within 4 to 5 months. All the 14 are right now at the pre-clinical trial stage."


However, the Minister cautioned that it is too early to expect any vaccine against the disease because there is a long due procedure involved in its development. "It will take minimum one year for the development of any vaccine even if it is developed earliest. Therefore use social distancing, masks and follow hand and physical hygiene -- the biggest safeguard against the disease -- till any vaccine or cure is found," said the Minister.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :CoronavirusVaccinehealthcare technologies

Next Story